1. Home ›
  2. News

News

WFCDD RFA Request for Applications-Now Open

The Warren Center for Drug Discovery invites new proposals for projects that are associated with drug discovery. In particular, projects associated with small molecule synthesis (libraries or molecular probes), hit validation, lead optimization, mid-sized scale up, assay development, protein purification, and ADMET screening. Any disease areas will be considered. Collaborative opportunities exist for the preparation of small molecules and/or computational-derived drug discovery via three cores: Chemical Synthesis & Drug Discovery, Computer-Aided Molecular Design, or Biological Screening and Development core. …

Read More

Welter Family Fellowship

Leah Cossin, a first-year graduate in the Taylor Lab is the second recipient of the Welter Family (Terri and Mark Welter) Graduate Fellowship in Science for research on Cystic Fibrosis. The Welter Family Fellowship in Science provides financial support to conduct research during the 2020-2021 academic year. This fellowship is focused on facilitating discoveries in cystic fibrosis research, which can include mechanistic studies, drug development, and/or related diseases, that affect those with Cystic Fibrosis (a genetic disease primarily affecting the lungs and respiratory function). Leah’s proposal focuses on the use of a small molecule splicing inhibitor, GEX1A, to affect the expression of mutated genes that lead to Cystic Fibrosis. Congratulations!…

Read More

Welter Family Fellowship

Veronica Hubble, a graduate student in the Melander lab, is the first recipient of the Welter Family graduate fellowship for research on Cystic Fibrous. The Welter Family Fellowship in Science provides financial support to conduct research during the 2019 academic year. This fellowship is aimed at facilitating discoveries in cystic fibrosis research, which can include mechanistic studies, drug development, and/or related diseases that affect those with CF (eg. infections of the lung). Veronica’s proposal was entitled “Using small molecule adjuvants to combat antibiotic resistant bacteria in cystic fibrosis.”…

Read More

Spring 2019 The Warren Roundup

As the 2018 academic year comes to an end, a summary of this year's accomplishments is provided in the annual Warren Roundup. First of all, several lead compounds have been identified by Notre Dame researchers and are undergoing preclinical evaluation, in hopes of identifying investigational new drugs (IND) for clinical evaluation.  …

Read More

Notre Dame technology licensed worldwide: Hsiri Therapeutics enters into a license and research collaboration agreement with Shionogi &Co., Ltd. for the treatment of mycobacterial diseases

University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM…

Read More

New Hope for the Treatment of Diabetic Foot Ulcers

In America, more than a million people suffer from diabetic foot ulcers.

In Latin, SalvePeds means “saving feet.” 

And in SalvePeds, a new IDEA Center startup managed and marketed by a team of graduate students at the University of Notre Dame, patients may soon have a more effective option to treat diabetic foot ulcers and prevent some of the 100,000 amputations the condition necessitates every year.…

Read More

Spring 2018 Warren Roundup Published

Welcome to the first edition of the Warren Roundup, wherein an attempt is made to summarize accomplishments by members of the Warren Family Research Center for Drug Discovery. In addition, you will find below a succinct summary of the services provided by each of the three scientific cores (synthesis, computational, and biological). Not only do I invite you to provide updates for inclusion in upcoming issues, but I also encourage you to learn more about the Warren Center cores and how they can help expedite your research.…

Read More

Indiana CTSI launching new program to engage Indiana residents in improving health through research

The Indiana Clinical and Translational Sciences Institute (CTSI), a research partnership among Indiana University, Purdue University and the University of Notre Dame, has launched a new program called “All IN for Health” to help grow public awareness of the state’s current health challenges and to invite the public’s participation into research studies taking place at our academic partner institutions.

Read More